For the first time, the same medicine as the Wegovy injection is available as a once-daily tablet. It has been approved in the US and, in June 2026, in the UK — and Europe's medicines regulator has recommended it too. Naturally, the question we hear most in Ireland is simple: can I get the Wegovy pill here?
The honest answer right now is no — but it is worth understanding what the pill actually is, how it compares to the injection, and what a doctor in Ireland can help you with today.
What is the Wegovy pill?
The Wegovy pill is oral semaglutide — the exact same active medicine as the Wegovy injection — one of the weight-loss injections available in Ireland — just in tablet form. It is made by Novo Nordisk, and the weight-management version is a once-daily 25 mg tablet. So it is not a new drug so much as a new format of a familiar one.
There is one important practical catch. Semaglutide is a peptide, and to be absorbed as a tablet it has to be taken carefully: on an empty stomach after fasting, with only a small sip of water, and then nothing to eat, drink or take for at least 30 minutes. That daily routine is stricter than the once-a-week injection, and it is worth factoring in.
Isn't this just Rybelsus?
Not quite. Rybelsus is also oral semaglutide, but it is licensed for type 2 diabetes at lower doses (up to 14 mg), not for weight loss. The new Wegovy tablet goes up to a higher 25 mg dose and is licensed specifically for weight management. It is also a different thing from the newer "small-molecule" pills in the headlines — orforglipron and elecoglipron — which are not semaglutide, have no food-and-water rules, and are still working through trials or early approvals.
How well does it work?
In its main trial (OASIS 4), adults with obesity taking the 25 mg tablet lost on average around 13–17% of their body weight over about 64 weeks, compared with roughly 2% on placebo. As with any of these figures, that is a trial average alongside diet and lifestyle support — not a promise, and individual results vary a lot. Around one in three participants lost at least a fifth of their body weight.
Because it is the same molecule, similar weight-loss results would be expected — though the pill has not been directly compared head-to-head with the injection. The trade-off is the daily routine and the strict way it has to be taken, rather than a once-weekly jab.
What about side effects?
Because it is semaglutide, the side-effect profile is the familiar one for this family of medicines: mostly gastrointestinal — nausea, vomiting, diarrhoea and constipation — usually mild to moderate and most common while the dose is being increased. None of this is medical advice; whether any GLP-1 medicine is appropriate for a given person is a clinical decision made with a doctor, which is exactly why medical supervision matters.
Did you know you can claim up to 75% back on your health insurance?
See how the claim works →Can you get the Wegovy pill in Ireland?
Not yet. The tablet is approved in the United States (December 2025) and the United Kingdom (June 2026), and the EU medicines regulator (the EMA) gave a positive recommendation in May 2026. But an EMA recommendation is not the final EU approval, that decision has not yet been confirmed, and the pill is not available in Ireland.
Even in the UK, approval has run ahead of supply — pharmacies there are still awaiting guidance on when it can actually be dispensed. A realistic Irish timeline is late 2026 into 2027 at the earliest, and, as with the injectables, it would almost certainly be available privately before any HSE reimbursement. So if you have seen the "weight-loss pill approved" headlines, the honest picture is: it is coming, but it is not here.
What you can do in Ireland today
While the tablet works its way through European approval, the established, licensed options for medical weight loss in Ireland are the injectable GLP-1 treatments — Mounjaro (tirzepatide) and Wegovy (semaglutide) — both available here on private prescription through doctor-led services. They are not currently reimbursed by the HSE for weight management, so they are paid privately. A proper service starts with a clinician checking that treatment is suitable and safe for you, rather than simply selling a product — you can read more in our complete guide to weight-loss treatment in Ireland.
Frequently asked questions
Is the Wegovy pill available in Ireland?
No. As of mid-2026 the oral Wegovy tablet is approved in the US and UK, and the EU medicines regulator has recommended it, but it has not received final EU approval and is not available in Ireland. A realistic Irish launch is late 2026 into 2027 at the earliest, likely on private prescription first.
Is the Wegovy pill the same as the injection?
Yes — it is the same active medicine, semaglutide, in a once-daily tablet instead of a weekly injection. The main practical difference is that the tablet must be taken on an empty stomach with a small sip of water, then nothing else for at least 30 minutes.
How much weight do people lose on the Wegovy pill?
In its main 64-week trial, people on the 25 mg tablet lost on average around 13–17% of their body weight, versus roughly 2% on placebo. That is a trial average alongside diet and lifestyle support — individual results vary and it is not a guaranteed outcome.
Is the Wegovy pill the same as orforglipron?
No. Orforglipron (and elecoglipron) are different, non-peptide "small-molecule" pills with no food or water rules, still at the trial or early-approval stage. The Wegovy pill is oral semaglutide — a peptide, with strict intake rules — and is the same molecule as the Wegovy injection.
What can I take in Ireland now?
The licensed medical weight-loss options in Ireland today are the injectable GLP-1s — Mounjaro (tirzepatide) and Wegovy (semaglutide) — prescribed privately through doctor-led services after a clinical assessment.
